Ampreloxetine

Ampreloxetine (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code name TD-9855) is a selective norepinephrine reuptake inhibitor (NRI) which is under development for the treatment of symptomatic neurogenic orthostatic hypotension (NOH).^[2][3][4]

Ampreloxetine

Clinical data
Other names	TD-9855
Drug class	Norepinephrine reuptake inhibitor; Serotonin–norepinephrine reuptake inhibitor
Pharmacokinetic data
Elimination half-life	30–40 hours[1]
Identifiers
IUPAC name 4-[2-[(2,4,6-trifluorophenoxy)methyl]phenyl]piperidine
CAS Number	1227056-84-9 Y[GSRS]
PubChem CID	46189893
DrugBank	DB15348
ChemSpider	64853713
UNII	19997EZ42I
KEGG	D11688
ChEMBL	ChEMBL4297646
Chemical and physical data
Formula	C18H18F3NO
Molar mass	321.343 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1CNCCC1C2=CC=CC=C2COC3=C(C=C(C=C3F)F)F
InChI InChI=1S/C18H18F3NO/c19-14-9-16(20)18(17(21)10-14)23-11-13-3-1-2-4-15(13)12-5-7-22-8-6-12/h1-4,9-10,12,22H,5-8,11H2 Key:TZIALEBTHQWNAO-UHFFFAOYSA-N

It shows high affinity for both the norepinephrine transporter (NET) and the serotonin transporter (SERT), with 4-fold selectivity for the NET over the SERT, and is thought to act as a dual serotonin–norepinephrine reuptake inhibitor (SNRI) at higher doses.^[4][1]

As of November 2023, ampreloxetine is in phase 3 clinical trials for NOH.^[2] The drug was also under development for the treatment of attention deficit hyperactivity disorder (ADHD) and fibromyalgia, but development for these uses was discontinued.^[2][5]